



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millionig
Donald J. Featherstone
Timothy J. Shea, Jr.
Lawrence B. Bugaisky
Michael V. Messinger
Judith U. Kim

Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Albert L. Ferro*
Donald R. Banowit
Peter A. Jackman
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Brian J. Del Buono
Virgil Lee Beaton
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhulier

Rae Lynn P. Guest
George S. Bardmesser
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Aric W. Ledford
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle*
Gaby L. Longworth
Lori A. Gordon
Nicole D. Dretar
Ted J. Ebersole
Jyoti C. Iyer

Laura A. Vogel
Michael J. Mancuso
Bryan S. Wade
Aaron L. Schwartz
Michael G. Penn*
Matthew E. Kelley*
Shannon A. Carroll*
Nicole R. Kramer*

Registered Patent Agents
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford

Michelle K. Holoubek
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse
Christopher J. Walsh
Liliana Di Nola-Baron
Peter A. Socarras

Of Counsel
Kenneth C. Bass III
Evan R. Smith
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to Federal Agencies

March 2, 2005

AS FILED 3/4/05

INTERNET ADDRESS:
JGOLD@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1644

Re: U.S. Patent Application
Application No. 10/690,639; Filed: October 23, 2003
For: **Pharmaceutical Composition of F(ab')₂ Antibody Fragments (As Amended)**
Inventors: de Silanes *et al.*
Our Ref: 2099.0010001/JAG/LAV

Sir:

Transmitted herewith for appropriate action are the following documents:

1. First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b) (3 pp.);
2. Form PTO-1449 listing 6 cited documents (2 pp);
3. One copy of 4 of the 6 cited documents (AM1, AN1, AT6, and AR7); and
4. Return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
March 2, 2005
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Jorge A. Goldstein
Attorney for Applicants
Registration No. 29,021

JAG/rjv
Enclosures

368733_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

de Silanes *et al.*

Appl. No.: 10/690,639

Filed: October 23, 2003

For: **Pharmaceutical Composition of
F(ab')₂ Antibody Fragments (As
Amended)**

Confirmation No.: 9165

Art Unit: 1644

Examiner: Yunsoo, Kim

Atty. Docket: 2099.0010001/JAG/LAV

First Supplemental Information Disclosure Statement

Under 37 C.F.R. § 1.97(b)

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Disclosure Statement is a continuation of the numbering on the Applicants' previous Information Disclosure Statement filed on August 20, 2004 in connection with the above-captioned application.

Copies of documents **AM1** and **AN1**, **AT6** and **AR7** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), no copies of U.S. patents and patent application publications cited on the attached Form PTO-1449 are submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits in accordance with 37 C.F.R. § 1.97(b)(3). No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Jorge A. Goldstein
Attorney for Applicants
Registration No. 29,021

Date: 3/4/05

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

365375.1

FORM PTO-1449

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
2099.0010001/JAG/LAV

APPLICATION NO.
10/690,639

FIRST NAMED INVENTOR
Silanes *et al.*

FILING DATE
October 23, 2003

ART UNIT 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF2	6,448,054 B1	09/10/2002	Poznansky <i>et al.</i>			04/07/2000
	AG2	2003/0049725 A1	03/13/2003	Heavner <i>et al.</i>			08/01/2001
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM1	WO 92/22324	12/23/1992	WIPO			Yes No
	AN1	WO 01/58469	08/16/2001	WIPO			Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT	<u>6</u>	Calderon-Aranda, E.S., <i>et al.</i> , "Neutralizing capacity of murine sera induced by different antigens of scorpion venom," <i>Toxicon</i> 31:327-337, Pergamon Press Ltd. (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENTATTY. DOCKET NO.
2099.0010001/JAG/LAVAPPLICATION NO.
10/690,639FIRST NAMED INVENTOR
Silanes *et al.*FILING DATE
October 23, 2003ART UNIT
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>7</u>	Licea, A.F., <i>et al.</i> , FAB fragments of the monoclonal antibody BCF2 are capable of neutralizing the whole venom from the scorpion <i>Centruroides noxius hoffman</i> ," <i>Toxicon</i> 34:843-847, Pergamon Press Ltd. (1996)
	AS	<u>7</u>	
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.